TrialCompass™ TCL
Back to trials
RecruitingPriority 2 · High priorityNCT06909877

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This trial is testing HH2853 Tablets for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

Who can join (key eligibility)

  • Age 18 Years to 75 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

HH2853 Tablets (DRUG): 25mg, 100mg and 200 mg BID oral administration

  • HH2853 Tablets

Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

Learn more

Use our AI Assistant

Ask questions about this trial, eligibility, or T-cell lymphoma in general.

Generate a letter for your doctor

Create a printable letter to discuss this trial with your oncologist.

TrialCompass — Clinical Trial Summary

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

NCT06909877

Phase: Phase 1, Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

This trial is testing HH2853 Tablets for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

Who can join

  • Age 18 Years to 75 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

HH2853 Tablets (DRUG): 25mg, 100mg and 200 mg BID oral administration

Drugs / treatments: HH2853 Tablets

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 100 patients

Primary endpoint: Phase Ib: To determine the RP2D of HH2853 in PTCL patients; Phase II: To evaluate the efficacy of HH2853 of R/R PTCL patients who have received at least one prior systemic combination chemotherapy and at least one new drug

Ages: 18 Years to 75 Years

Start date: 2022-07-27 | Est. completion: 2027-07-30

Locations

0 US sites · 1 total

Contact

Haiying Jia | haiying.jia@haihepharma.com | 86-20568888

Sponsor: Haihe Biopharma Co., Ltd. (INDUSTRY)

Tags

All T-cell lymphomas · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06909877

Prepared using TrialCompass (trialcompass.com) on August 3, 2026. For informational purposes only. Always discuss with your healthcare team.